This site is intended for healthcare professionals

Mirikizumab up-regulates genes associated with mucosal healing in ulcerative colitis for up to one year in phase II study.- Eli Lilly.

Read time: 3 mins
Last updated:28th Jul 2021
Published:10th Jul 2021
Eli Lilly and Company announced new Phase II data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year.
Condition: Ulcerative Colitis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest